Pregnenolones may be a biomarker for diagnosing pituitary stalk interruption syndrome

Posted on July 19, 2022

In this study, basal information and seminal plasma samples were collected from 21 patients with Pituitary stalk interruption syndrome (PSIS) and 23 healthy controls.

In patients with PSIS, there were changes in the metabolomics and lipidomics profiles, with prolactin signaling pathway and biosynthesis of amino acids the main differentially modified metabolic pathways.

Pregnenolones and L-saccharopine were potential biomarkers for a diagnosis of PSIS and the main differentially modified metabolites were triacylglycerols, phosphatidylethanolamine, sphingomyelin, ceramide, and phosphatidylcholines.

Supplementation has the potential to improve spermatogenesis, the authors included, although future studies are needed to verify this.

Guo Y, Li X, Wang X, et al. Seminal plasma metabolomics and lipidomics profiling to identify signatures of pituitary stalk interruption syndrome. Orphanet J Rare Dis; 2022:https://doi.org/10.1186/s13023-022-02408-4.